GC
Therapeutic Areas
Theriva Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VCN-01 (zabilugene almadenorepvec) | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 |
| VCN-01 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 |
| Albumin Shield™-Enabled OV | Undisclosed Solid Tumors | Preclinical |
Leadership Team at Theriva Biologics
SS
Steven Shallcross
Chief Executive Officer, Chief Financial Officer, Director
MC
Manel Cascallo
General Director, EU Subsidiary
VW
Vince Wacher
Head of Corporate & Product Development
RA
Ramon Alemany
Scientific Advisor
JT
Josep Tabernero
Scientific Advisor
JJ
Jeffrey J. Kraws
Chairman of the Board
JW
Jeffrey Wolf
Director
JM
John Monahan
Director